Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. Helft PR, et al. Among authors: lambert jm. Clin Cancer Res. 2004 Jul 1;10(13):4363-8. doi: 10.1158/1078-0432.CCR-04-0088. Clin Cancer Res. 2004. PMID: 15240523 Clinical Trial.
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK. Tolcher AW, et al. Among authors: lambert jm. J Clin Oncol. 2003 Jan 15;21(2):211-22. doi: 10.1200/JCO.2003.05.137. J Clin Oncol. 2003. PMID: 12525512 Clinical Trial.
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Rodon J, et al. Among authors: lambert jm. Cancer Chemother Pharmacol. 2008 Oct;62(5):911-9. doi: 10.1007/s00280-007-0672-8. Epub 2008 Feb 27. Cancer Chemother Pharmacol. 2008. PMID: 18301896 Clinical Trial.
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Younes A, et al. Among authors: lambert jm. J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753910 Free PMC article. Clinical Trial.
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Lewis Phillips GD, et al. Among authors: lambert jm. Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776. Cancer Res. 2008. PMID: 19010901
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Lynch TJ Jr, et al. Among authors: lambert jm. J Clin Oncol. 1997 Feb;15(2):723-34. doi: 10.1200/JCO.1997.15.2.723. J Clin Oncol. 1997. PMID: 9053498 Clinical Trial.
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blättler WA, Chari RV. Liu C, et al. Among authors: lambert jm. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8618-23. doi: 10.1073/pnas.93.16.8618. Proc Natl Acad Sci U S A. 1996. PMID: 8710920 Free PMC article.
207 results